| Primary |
| Hypertension |
31.9% |
| Cardiac Failure |
14.4% |
| Atrial Fibrillation |
5.4% |
| Diabetes Mellitus |
5.3% |
| Drug Use For Unknown Indication |
4.9% |
| Ascites |
4.3% |
| Essential Hypertension |
4.1% |
| Cardiac Failure Congestive |
3.2% |
| Prophylaxis |
3.2% |
| Hepatic Cirrhosis |
3.0% |
| Ill-defined Disorder |
2.7% |
| Oedema |
2.5% |
| Oedema Peripheral |
2.5% |
| Type 2 Diabetes Mellitus |
2.4% |
| Asthma |
1.9% |
| Pain |
1.8% |
| Acne |
1.7% |
| Depression |
1.6% |
| Cardiac Failure Chronic |
1.5% |
| Arrhythmia |
1.4% |
|
| Renal Failure Acute |
20.5% |
| Hyperkalaemia |
12.3% |
| Hepatic Encephalopathy |
7.5% |
| Renal Failure |
7.5% |
| Death |
6.1% |
| Hyponatraemia |
5.3% |
| Drug Interaction |
4.8% |
| Platelet Count Decreased |
3.9% |
| Syncope |
3.9% |
| Thrombocytopenia |
3.7% |
| Vomiting |
3.2% |
| Malaise |
3.0% |
| Rash |
2.9% |
| Somnolence |
2.9% |
| Gynaecomastia |
2.3% |
| Fall |
2.1% |
| Interstitial Lung Disease |
2.1% |
| Hypotension |
2.0% |
| Toxic Epidermal Necrolysis |
2.0% |
| Weight Decreased |
2.0% |
|
| Secondary |
| Hypertension |
23.3% |
| Product Used For Unknown Indication |
21.3% |
| Drug Use For Unknown Indication |
17.7% |
| Cardiac Failure |
8.0% |
| Atrial Fibrillation |
3.4% |
| Prophylaxis |
3.1% |
| Diabetes Mellitus |
2.8% |
| Ill-defined Disorder |
2.6% |
| Psoriatic Arthropathy |
2.2% |
| Asthma |
1.7% |
| Pain |
1.7% |
| Myocardial Infarction |
1.6% |
| Essential Hypertension |
1.4% |
| Constipation |
1.4% |
| Type 2 Diabetes Mellitus |
1.4% |
| Depression |
1.4% |
| Hepatitis C |
1.3% |
| Oedema Peripheral |
1.3% |
| Hypothyroidism |
1.3% |
| Ascites |
1.2% |
|
| Renal Failure Acute |
24.5% |
| Renal Failure |
11.0% |
| Hyperkalaemia |
8.9% |
| Hyponatraemia |
8.5% |
| Vomiting |
5.2% |
| Syncope |
4.5% |
| Toxic Epidermal Necrolysis |
4.2% |
| Renal Impairment |
3.2% |
| Death |
2.9% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.9% |
| Hepatitis Acute |
2.8% |
| Malaise |
2.8% |
| Hypotension |
2.6% |
| Liver Disorder |
2.6% |
| Hepatic Encephalopathy |
2.5% |
| Pyrexia |
2.3% |
| Thrombocytopenia |
2.2% |
| Somnolence |
2.1% |
| Toxic Skin Eruption |
2.1% |
| White Blood Cell Count Decreased |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.7% |
| Drug Use For Unknown Indication |
15.7% |
| Hypertension |
14.2% |
| Prophylaxis |
5.9% |
| Cardiac Failure |
5.4% |
| Atrial Fibrillation |
4.0% |
| Diabetes Mellitus |
4.0% |
| Pulmonary Arterial Hypertension |
3.5% |
| Hepatic Neoplasm Malignant |
3.1% |
| Pain |
3.0% |
| Pulmonary Hypertension |
2.4% |
| Cardiac Failure Chronic |
2.3% |
| Hepatitis C |
2.3% |
| Constipation |
2.0% |
| Cardiac Failure Congestive |
2.0% |
| Rheumatoid Arthritis |
1.9% |
| Depression |
1.9% |
| Insomnia |
1.9% |
| Cardiac Disorder |
1.8% |
| Multiple Myeloma |
1.8% |
|
| Vomiting |
11.9% |
| Weight Increased |
8.5% |
| Weight Decreased |
6.6% |
| Renal Failure Acute |
6.4% |
| Death |
6.3% |
| Renal Failure |
5.6% |
| Thrombocytopenia |
5.2% |
| Pyrexia |
4.4% |
| White Blood Cell Count Decreased |
4.4% |
| Cardiac Failure |
4.4% |
| Pneumonia |
4.4% |
| Urinary Tract Infection |
4.4% |
| Renal Impairment |
3.9% |
| Ventricular Tachycardia |
3.7% |
| Rash |
3.7% |
| Respiratory Failure |
3.4% |
| White Blood Cell Count Increased |
3.4% |
| Platelet Count Decreased |
3.2% |
| Interstitial Lung Disease |
3.1% |
| Somnolence |
3.1% |
|
| Interacting |
| Hypertension |
17.9% |
| Cardiac Failure |
14.7% |
| Ascites |
8.4% |
| Drug Use For Unknown Indication |
8.2% |
| Product Used For Unknown Indication |
8.2% |
| Atrial Fibrillation |
6.5% |
| Ill-defined Disorder |
5.7% |
| Hypertensive Heart Disease |
4.6% |
| Diabetes Mellitus |
4.2% |
| Cardiomyopathy |
3.4% |
| Asthma |
2.7% |
| Prophylaxis |
2.7% |
| Hepatic Cirrhosis |
1.9% |
| Essential Hypertension |
1.7% |
| Gastritis Prophylaxis |
1.7% |
| Myocardial Ischaemia |
1.7% |
| Depression |
1.5% |
| Renal Osteodystrophy |
1.5% |
| Type 2 Diabetes Mellitus |
1.5% |
| Cardiac Failure Congestive |
1.3% |
|
| Renal Failure Acute |
25.6% |
| Drug Interaction |
12.0% |
| Hyperkalaemia |
12.0% |
| Hepatic Encephalopathy |
8.3% |
| Hyponatraemia |
7.5% |
| Vomiting |
5.3% |
| Hypotension |
3.8% |
| Renal Failure |
3.0% |
| Renal Failure Chronic |
3.0% |
| Ventricular Tachycardia |
3.0% |
| Nausea |
2.3% |
| Somnolence |
2.3% |
| Blood Sodium Decreased |
1.5% |
| Bradycardia |
1.5% |
| Heart Rate Decreased |
1.5% |
| Malaise |
1.5% |
| Metabolic Alkalosis |
1.5% |
| Rectal Ulcer Haemorrhage |
1.5% |
| Syncope |
1.5% |
| Urinary Tract Infection |
1.5% |
|
